Abiomed (ABMD) Tops Q3 EPS by 26c, Raises FY Guidance

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $0.30, $0.26 better than the analyst estimate of $0.04. Revenue for the quarter came in at $62 million versus the consensus estimate of $53.2 million.

FISCAL YEAR 2015 OUTLOOK

The Company is increasing its fiscal year 2015 guidance for total revenue to be in the range of $223 million to $226 million, an increase of 21% to 23% from the prior year. This new range compares to the previous range of $209 million to $212 million, which represented an increase of 14% to 15% from the prior year. The Company is also increasing its fiscal year 2015 guidance for GAAP operating margin to be in the range of 9% to 11% from the previous range of 1% to 4%.

The Company's fiscal year period ends on March 31, 2015. Currently, the Company is estimating fiscal year 2016 revenue in the range of $260 million to $270 million and upon completion of the fourth quarter will provide formal guidance during the earnings call, expected in early May 2015.

(Street sees FY15 revenue of $248.60M)

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c